Sepracor faces setbacks with two drugs
06 July 2009
Katie McQue
Please Login to read the full article.
06 July 2009
Katie McQue
katie.mcque@informa.com
Sepracor has been hit with a double setback as its mid-stage antidepressant SEP-225289 failed a Phase II study, and two paediatric studies of its best-selling sedative Lunesta (eszopiclone) have been placed on hold.
The company's shares fell by 18% to $14.67 on Nasdaq on July 2nd.
SEP-225289
SEP-225289...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Alkermes' PhII ALKS-5461: new mechanism, opiate receptor modulation, for refractory depression
- Major disappointment for Targacept and AstraZeneca in Phase III depression trial
- Dainippon Sumitomo hit by Asian trial setback for lurasidone
- New Japanese approvals include Xarelto for stroke prevention
COMMENT
Other Informa Comment
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
